Company Description
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S.
pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities.
The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers.
ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 647 |
| CEO | Adam Grossman |
Contact Details
Address: 465 State Route 17 Ramsey, New Jersey 07446 United States | |
| Phone | 201 478 5552 |
| Website | admabiologics.com |
Stock Details
| Ticker Symbol | ADMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001368514 |
| CUSIP Number | 000899104 |
| ISIN Number | US0008991046 |
| Employer ID | 56-2590442 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Adam S. Grossman | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Jerrold B. Grossman D.P.S., Ph.D. | Co-Founder and Vice Chairman of the Board |
| P. Terence Kohler | Chief Financial Officer and Treasurer |
| Kaitlin M. Kestenberg | Chief Operating Officer and Senior Vice President of Compliance |
| Brad L. Tade | Consultant |
| Michael Goldstein | General Counsel |
| John Hafl | Executive Director of Sales |
| Skyler Bloom | Senior Director of Business Development and Corporate Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2026 | SCHEDULE 13G | Filing |
| Apr 15, 2026 | ARS | Filing |
| Apr 15, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 15, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2026 | 8-K | Current Report |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 10, 2026 | 144 | Filing |
| Mar 9, 2026 | 144 | Filing |
| Mar 2, 2026 | 8-K | Current Report |
| Feb 25, 2026 | 10-K | Annual Report |